A Phase 4 clinical trial involving setmelanotide entered recruiting status as of June 29, 2026. The study, registered as NCT07674290, is titled "Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity." Setmelanotide is an approved MC4R agonist therapy. This Phase 4 designation indicates the trial is being conducted after regulatory approval, typically to gather additional real-world data. The trial status is currently listed as recruiting, meaning it is actively seeking participants. No results or outcome data have been posted for this study at this time. The trial is registered on ClinicalTrials.gov under the identifier NCT07674290, where further details on eligibility and study design can be found. This update reflects only the recruiting status and trial title as registered on the specified date. No efficacy, safety, or interim findings are reported as part of this update. Readers interested in setmelanotide's approved uses and background can consult the compound overview for additional context.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT07674290"]